PMID- 27006706
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160323
LR  - 20220408
IS  - 1758-5996 (Print)
IS  - 1758-5996 (Electronic)
IS  - 1758-5996 (Linking)
VI  - 8
DP  - 2016
TI  - Dipeptidyl peptidase-4 inhibitors improve arterial stiffness, blood pressure, 
      lipid profile and inflammation parameters in patients with type 2 diabetes 
      mellitus.
PG  - 26
LID - 10.1186/s13098-016-0144-6 [doi]
LID - 26
AB  - BACKGROUND: This uncontrolled open label study evaluated the effect of dipeptidyl 
      peptidase-4 inhibitors (DPP-4i): sitagliptin and vildagliptin on augmentation 
      index standardized for 75 beats per minute (cAiX@75), blood pressure (BP), lipid 
      profile and high-sensitivity C-reactive protein (hsCRP) in patients with type 2 
      diabetes mellitus (T2DM). METHODS: Fifty-one well-regulated T2DM patients were 
      randomly assigned to either sitagliptin or vildagliptin (100 mg/day) for 3 months 
      continuing their previous treatment. Lipid profile, cAiX@75, hsCRP, glycated 
      hemoglobin (HbA1c) were measured at baseline at 4, 8 and 12th week were accessed. 
      cAiX@75 and pulse wave velocity (PWV) were determined by SphygmoCor device. 
      RESULTS: Following DPP-4 treatment there was a significant reduction in total 
      serum cholesterol (5.18 vs 4.62 mmol/L), low-density lipoprotein (2.89 vs 
      2.54 mmol/L), hsCRP (3.21 vs 1.95 mg/L), cAiX@75 (24.5 vs 22.3) and central 
      systolic BP (131.8 vs 119.5 mmHg). The sitagliptin treated group reached cAiX@75 
      reduction earlier in the study period while neither sitagliptin or vildagliptin 
      use resulted in the significant HbA1c reduction. CONCLUSION: The treatment with 
      DPP-4i: sitagliptin and vildagliptin provides favorable metabolic and vascular 
      effects beyond glucose-control. Further studies are required to elucidate their 
      implication in metabolic pathways.
FAU - Duvnjak, Lea
AU  - Duvnjak L
AD  - Vuk Vrhovac Clinic for Diabetes, Endocrinology and Metabolic diseases, Merkur 
      University hospital, Dugi dol 4a, Zagreb, Croatia ; School of Medicine, 
      University of Zagreb, Zagreb, Croatia.
FAU - Blaslov, Kristina
AU  - Blaslov K
AD  - Vuk Vrhovac Clinic for Diabetes, Endocrinology and Metabolic diseases, Merkur 
      University hospital, Dugi dol 4a, Zagreb, Croatia.
LA  - eng
PT  - Journal Article
DEP - 20160322
PL  - England
TA  - Diabetol Metab Syndr
JT  - Diabetology & metabolic syndrome
JID - 101488958
PMC - PMC4802883
OTO - NOTNLM
OT  - Augumentation index
OT  - Blood pressure
OT  - Dipeptidyl peptidase-4
OT  - Type 2 diabetes mellitus
EDAT- 2016/03/24 06:00
MHDA- 2016/03/24 06:01
PMCR- 2016/03/22
CRDT- 2016/03/24 06:00
PHST- 2015/12/15 00:00 [received]
PHST- 2016/03/09 00:00 [accepted]
PHST- 2016/03/24 06:00 [entrez]
PHST- 2016/03/24 06:00 [pubmed]
PHST- 2016/03/24 06:01 [medline]
PHST- 2016/03/22 00:00 [pmc-release]
AID - 144 [pii]
AID - 10.1186/s13098-016-0144-6 [doi]
PST - epublish
SO  - Diabetol Metab Syndr. 2016 Mar 22;8:26. doi: 10.1186/s13098-016-0144-6. 
      eCollection 2016.